We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Amino Acid Balance During Physical Inactivity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02980952
Recruitment Status : Not yet recruiting
First Posted : December 2, 2016
Last Update Posted : December 2, 2016
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The aim is to assess the impact of physical inactivity on muscle amino acid balance. In addition, we will evaluate how the diet and/or a pharmacological intervention designed to manipulate lipid metabolism (acipimox) will modulate muscle amino acid balance.

Condition or disease Intervention/treatment
Assessing Muscle Amino Acid Balance Other: overfeeding Drug: Acipimox Other: Physical inactivity Dietary Supplement: Eucaloric Dietary Supplement: Placebo Dietary Supplement: Hypercaloric

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: Amino Acid Balance During Physical Inactivity
Study Start Date : January 2017
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Placebo Comparator: Eucaloric + placebo
Fed in energy balance with a placebo supplement
Other: Physical inactivity Dietary Supplement: Eucaloric Dietary Supplement: Placebo
Experimental: Eucaloric + acipimox
Fed in energy balance with an acipimox supplement
Drug: Acipimox
Acipimox ingestion
Other: Physical inactivity Dietary Supplement: Eucaloric
Experimental: Hypercaloric + placebo
Fed in energy surplus with a placebo supplement
Other: overfeeding Other: Physical inactivity Dietary Supplement: Placebo Dietary Supplement: Hypercaloric
Experimental: Hypercaloric + acipimox
Fed in energy surplus with an acipimox supplement
Other: overfeeding Drug: Acipimox
Acipimox ingestion
Other: Physical inactivity Dietary Supplement: Hypercaloric


Outcome Measures

Primary Outcome Measures :
  1. Muscle amino acid balance [ Time Frame: 3 hours ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • BMI between 18 and 30

Exclusion Criteria:

  • On medication
  • Family history of metabolic disease
  • Diagnosed with any metabolic or cardiovascular conditions
  • BMI <18 or >30
  • Allergic to acipimox
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02980952


Contacts
Contact: Benjamin T Wall, PhD +4413927224774 ext 4774 b.t.wall@exeter.ac.uk

Sponsors and Collaborators
University of Exeter
More Information

Responsible Party: University of Exeter
ClinicalTrials.gov Identifier: NCT02980952     History of Changes
Other Study ID Numbers: 157758/03
First Posted: December 2, 2016    Key Record Dates
Last Update Posted: December 2, 2016
Last Verified: November 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Acipimox
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents